Repligen (RGEN) has received a new Buy rating, initiated by HSBC analyst, Sidharth Sahoo.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sidharth Sahoo has given his Buy rating due to a combination of factors that highlight Repligen’s potential for significant growth. The company is positioned as a leader in the bioprocessing sector, which is one of the fastest-growing areas within life sciences. Repligen’s ability to innovate rapidly and its broad product portfolio provide it with a competitive edge, allowing it to surpass the growth rates of its larger peers. Additionally, the company’s strategy to adopt a local-for-local approach helps mitigate the challenges posed by tariffs and regulatory barriers, potentially boosting new equipment and consumable orders.
Sidharth Sahoo also considers the financial metrics and market conditions in his analysis. The reverse discounted cash flow analysis suggests that the current share price may not fully reflect Repligen’s growth potential, with an estimated revenue growth rate of around 12%. The target price set at USD150.00 indicates a potential upside of approximately 19%. While there are concerns about the biotech funding cycle and competition from industry giants, the overall structural growth of the industry and potential improvements in regulatory conditions present attractive opportunities for Repligen’s stock.
Sahoo covers the Healthcare sector, focusing on stocks such as Thermo Fisher, Repligen, and Labcorp Holdings. According to TipRanks, Sahoo has an average return of -1.4% and a 27.27% success rate on recommended stocks.
In another report released on September 23, Craig-Hallum also maintained a Buy rating on the stock with a $0.00 price target.